digital currency conference, snippets

Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.On the evening of December 10th, Google released a new generation of quantum computing chip Willow, which caused a great sensation in the global scientific and technological community. It is reported that this is a major breakthrough in the field of quantum computing-this field is regarded as the next technological frontier of many technology companies.This afternoon, the Government of the Hong Kong Special Administrative Region welcomed the passage of the Stamp Duty Legislation (Miscellaneous Amendments) Bill 2024 by the Legislative Council, which exempted the transfer of shares or units of real estate investment trusts and the securities distribution business of option makers, and revised the stamp duty collection arrangements under the paperless securities market system in Hong Kong.

At present, there is nothing wrong with the medium and long-term trend, so don't worry too much. Strategically, we will continue to watch more. Tactically, we will follow the trend and take the initiative step by step.The previous wave of adjustment of the Hang Seng Index was to step back on the long-term trend line at the daily level, which gained support and rebounded recently. Today, it closed above the offensive line, and the long-term trend at the daily level remains intact. On the monthly level, it fell below the offensive line last month, but it is above the offensive line at present, and it closed above 19,738 points this month. The problem is not big, and the long-term trend remains intact, and there is a basis for further strength.The latest progress of stamp duty in Hong Kong has come!

Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Shanghai stock exchange recently released